MetLife Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

MetLife Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,582	Closed	-$88.3K	–	2812
2024 Q3	$88.3K	Buy	12,582 +7,089	+129%	+$51.5K	﹤0.01%	2672
2024 Q2	$37.7K	Buy	+5,493	New	+$51.1K	﹤0.01%	2808
2021 Q2	–	Sell	-2,389	Closed	-$236K	–	2438
2021 Q1	$236K	Sell	2,389 -1,373	-36%	-$165K	﹤0.01%	1966
2020 Q4	$408K	Hold	3,762	–	–	﹤0.01%	1587
2020 Q3	$387K	Buy	3,762 +501	+15%	+$75K	﹤0.01%	1504
2020 Q2	$681K	Buy	3,261 +405	+14%	+$71.7K	0.01%	1211
2020 Q1	$279K	Hold	2,856	–	–	﹤0.01%	1512
2019 Q4	$329K	Hold	2,856	–	–	﹤0.01%	1686
2019 Q3	$156K	Hold	2,856	–	–	﹤0.01%	2081
2019 Q2	$340K	Hold	2,856	–	–	﹤0.01%	1718
2019 Q1	$150K	Buy	+2,856	New	+$115K	﹤0.01%	2145
2018 Q4	–	Sell	-2,834	Closed	-$171K	–	2569
2018 Q3	$171K	Hold	2,834	–	–	﹤0.01%	2175
2018 Q2	$150K	Buy	+2,834	New	+$170K	﹤0.01%	2052

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's ADVM Position: Q4 2024 in Review

MetLife Investment Management sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 12,582 shares — an estimated $88.3K sold.

MetLife Investment Management first reported a position in ADVM in Q2 2018 and held it in 13 quarters. The position peaked at $681K in Q2 2020. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

MetLife Investment Management reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
MetLife Investment Management sold 12,582 Adverum Biotechnologies shares in Q4 2024, an estimated $88.3K.
MetLife Investment Management first reported a position in Adverum Biotechnologies in Q2 2018 and held it in 13 quarters.
MetLife Investment Management's Adverum Biotechnologies position peaked at $681K in Q2 2020.
69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.